IMMEDIATE RELEASE 4-METHYL-3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]- N-[5-(4-METHYL- 1H-IMIDAZOL-1-YL)-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE FORMULATION 4--3[[4-(3-)-2-]]-N-[5-(4--1H--1- )-3-()]

A solid dosage form of nilotinib is disclosed that comprises: (i) a core comprising 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide or a pharmaceutically acceptable salt thereof and excipients; and (ii) at least one polymer, sai...

Full description

Saved in:
Bibliographic Details
Main Authors LI, PING, COMFORT, ANN REESE, MAKAROV, ALEXEY, LI, SHOUFENG, BHARDWAJ, UPKAR, BORDAWEKAR, MANGESH SADASHIV
Format Patent
LanguageChinese
English
Published 02.01.2015
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

Abstract A solid dosage form of nilotinib is disclosed that comprises: (i) a core comprising 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide or a pharmaceutically acceptable salt thereof and excipients; and (ii) at least one polymer, said polymer coating said core, wherein disintegration of said solid dosage form is delayed.
AbstractList A solid dosage form of nilotinib is disclosed that comprises: (i) a core comprising 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide or a pharmaceutically acceptable salt thereof and excipients; and (ii) at least one polymer, said polymer coating said core, wherein disintegration of said solid dosage form is delayed.
Author BHARDWAJ, UPKAR
LI, SHOUFENG
BORDAWEKAR, MANGESH SADASHIV
COMFORT, ANN REESE
LI, PING
MAKAROV, ALEXEY
Author_xml – fullname: LI, PING
– fullname: COMFORT, ANN REESE
– fullname: MAKAROV, ALEXEY
– fullname: LI, SHOUFENG
– fullname: BHARDWAJ, UPKAR
– fullname: BORDAWEKAR, MANGESH SADASHIV
BookMark eNqNjr1OwzAUhTPAAKXv4DEZjlTXrRCjITeyVf9Uxh3SyKoqZCaUVioPyKOR9IeZ6epI53zffSzu-kOfH4ofbS3VWkZigQzJd2ILWIqqNRDougVKgXUbdK1dayrMz8FeYpJWO5_AHLolyr8h4wpjR269Ace4Eyhj0I3Z-OAvrWqtaGS8ktsOnJpY44PdGBm1d8MTEFf7KE0JNwcG-ABlZ2aVnor7z_3XKU-vd1KwhuKbQj4edvl03H_kPn_v1Irzl-fZfCm5-EflF3QTTBQ
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate 即釋 -甲基- -吡啶基 -嘧啶基 氨基 -甲基- -咪唑- -基 三氟甲基 苯基 苯甲酰胺劑型
ExternalDocumentID HK1197025A1
GroupedDBID EVB
ID FETCH-epo_espacenet_HK1197025A13
IEDL.DBID EVB
IngestDate Fri Jul 19 14:56:34 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language Chinese
English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_HK1197025A13
Notes Application Number: HK20140110470
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20150102&DB=EPODOC&CC=HK&NR=1197025A1
ParticipantIDs epo_espacenet_HK1197025A1
PublicationCentury 2000
PublicationDate 20150102
PublicationDateYYYYMMDD 2015-01-02
PublicationDate_xml – month: 01
  year: 2015
  text: 20150102
  day: 02
PublicationDecade 2010
PublicationYear 2015
Score 2.9649053
Snippet A solid dosage form of nilotinib is disclosed that comprises: (i) a core comprising...
SourceID epo
SourceType Open Access Repository
SubjectTerms HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Title IMMEDIATE RELEASE 4-METHYL-3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]- N-[5-(4-METHYL- 1H-IMIDAZOL-1-YL)-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE FORMULATION 4--3[[4-(3-)-2-]]-N-[5-(4--1H--1- )-3-()]
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20150102&DB=EPODOC&locale=&CC=HK&NR=1197025A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT8JAEN4QNOpNUSO-0oNp4DCRvngciCntklb6ILUYkDSkLSXhAkQw_j1_mrNLQS9667a73zSzmc5-sztTQh6akpo16lPkJmktRoKixRA3JA1qcaOlpcp0Jqcs39n16tZAfR5qwwKZ73JheJ3QT14cES0qRXvf8O_16ieIZfKzlevHZI63lk_dsG2KOTvG1Q06TNHstGnfN31DNIy21RO9oM12y9C960iUDnAV3WDGQF87LCll9dujdE_JYR_BFpszUsgWJXJs7H68ViJHbr7fjZe56a3PyZftslKMekiFgDpUf6GCCi4NrZEDCozHKlQU6I8C27S9kVMFmTfcbTPSXdvzIxA8GGtQ2Q8UJAtYH_3Nd5DlsXEKVMLA7joDP_C3vap9izKMDvXeEMekAjJHd-Dw6Ba-BCi5dCY0imAnAxAcQQWOWY0uiNCloWEBqmKyV_vE6u2VplyS4mK5yK6IoMhJrNbiLNXkmZpKs6aKykyVTJaSaQsXk2VS_hPm-p9nN-SEzR-Pbsi3pLh5_8ju0N9vkns-U9_-Pp6N
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT8JAEN4QNeJNUSM-ezANHCbSF48DMaVd0kofpBbDIw0ppSRcgAjGv-dPc3Yp6EVv3Xb3m2Y209lvdmdKyGNdUtNadYrcJKnESFC0GOKapEElrjW0RJnO5ITlO7te1eqpL32tnyPzXS4MrxP6yYsjokUlaO8b_r1e_QSxTH62cv00meOt5XM7bJpixo5xdYMOUzRbTdr1Td8QDaNpdUQvaLLdMnTvOhKlQ1xh15gx0LcWS0pZ_fYo7VNy1EWwxeaM5NJFgeSN3Y_XCuTYzfa78TIzvfU5-bJdVopRD6kQUIfqr1RQwaWhNXBAgdFIhZIC3UFgm7Y3cMog84a7bUa6a3t-BIIHIw1K-4GCZAHrow99B1keG6dAKQzsttPzA3_bq9y1KMNoUW-IOCYVkDm6PYdHt_AlQMmkM6FRBDsZgOAIKnDMcnRBhDYNDQtQFeO92sdWZ6805ZIcLJaL9IoIijyJ1UqcJpo8UxNpVleRsSRKKkuTaQMXk0VS_BPm-p9nDyRvha4zdmyvc0NO2FzySId8Sw427x_pHfr-zeSez9o3nhahgA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=IMMEDIATE+RELEASE+4-METHYL-3-%5B%5B4-%283-PYRIDINYL%29-2-PYRIMIDINYL%5DAMINO%5D-+N-%5B5-%284-METHYL-+1H-IMIDAZOL-1-YL%29-3-%28TRIFLUOROMETHYL%29PHENYL%5DBENZAMIDE+FORMULATION+4--3%5B%5B4-%283-%29-2-%5D%5D-N-%5B5-%284--1H--1-+%29-3-%28%29%5D&rft.inventor=LI%2C+PING&rft.inventor=COMFORT%2C+ANN+REESE&rft.inventor=MAKAROV%2C+ALEXEY&rft.inventor=LI%2C+SHOUFENG&rft.inventor=BHARDWAJ%2C+UPKAR&rft.inventor=BORDAWEKAR%2C+MANGESH+SADASHIV&rft.date=2015-01-02&rft.externalDBID=A1&rft.externalDocID=HK1197025A1